Corvus Pharmaceuticals has released the preclinical data and preclinical biomarker data from its Phase 1/1b CPI-444 clinical study.
The ongoing CPI-444 clinical trial was designed to study the drug as a single agent as well as combined with TECENTRIQ, Genetech’s monoclonal antibody.
“We are very encouraged by the early data showing that CPI-444 is well tolerated and by the biomarker data indicating that treatment with CPI-444 as a single agent is associated with activation of T-cells detected in the blood. We believe this is the first demonstration of immune modulation in cancer patients receiving an adenosine antagonist,” Corvus President and CEO Dr. Richard Miller said. “Patient enrollment in our CPI-444 Phase 1/1b study is on schedule, and we anticipate completing the dose-selection portion of the study and reporting interim safety and efficacy data at a scientific conference later this year. That data will enable us to choose the best dose for testing in disease-specific expansion cohorts, which we expect to initiate before year end.”
The data from the CPI-444 clinical study was presented at the Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival by Corvus Senior Scientist Stephen Willingham.